ArticleBreast cancer research : BCR2025

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.

Rebecca Dent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.